Income statement
USD
Annual
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 789K | 881K | 0 | 0 | 0 |
| Gross Profit | 564K | 694K | 0 | 0 | 0 |
| Operating Income | -298K | -147K | -38K | -32K | -33K |
| EBITDA | -293K | -71K | -45K | -38K | -32K |
| Net Income | -7M | -145K | -38K | -32K | -33K |
| EPS (Diluted) | — | — | — | — | — |
Industrials
Live Price
Offline$0.0002
+0.00% today
Window Change
+0.00%
Window
May 29, 2026 → Jun 11, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 10 bars · May 29, 2026 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Proto Script Pharmaceutical Corp. (PSCR) is a Industrials stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (May 29, 2026 → Jun 11, 2026). Baseline metrics include revenue growth of -10.5%, EPS growth of -1493.8%, a dividend yield of 0.0%. What stands out right now is revenue -10.5%, EPS -1493.8%, free cash flow -9.8% with operating margin -37.8% and ROIC 111.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PSCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSCR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PSCR Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PSCR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$32.8K
-1.3% YoY
Free Cash Flow
-$23.7K
+25.9% YoY
Revenue Growth
-10.5%
EPS Growth
-1493.8%
Gross Margin
71.5%
Net Margin
-910.4%
Income statement
USD
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 789K | 881K | 0 | 0 | 0 |
| Gross Profit | 564K | 694K | 0 | 0 | 0 |
| Operating Income | -298K | -147K | -38K | -32K | -33K |
| EBITDA | -293K | -71K | -45K | -38K | -32K |
| Net Income | -7M | -145K | -38K | -32K | -33K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4K | 9K | 40 | 35K | 60K |
| Total Assets | 170K | 199K | 311 | 36K | 61K |
| Total Liabilities | 490K | 137K | 28K | 8K | 9K |
| Shareholder Equity | -320K | 62K | -28K | 28K | 52K |
| Total Debt | 51K | 36K | 0 | 0 | 0 |
| Net Debt | 48K | 27K | -40 | -35K | -60K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24K
+25.9% YoY
Capital Expenditures
0
Free Cash Flow
24K
+25.9% YoY
Key ratios
Gross Margin
71.5%
Operating Margin
-37.8%
Net Margin
-910.4%
ROE
5578.9%
Debt / Equity
-0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.